Four EU countries secure access to Oxford vaccine as AZ’s dose commitments exceed 2B

BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.

AstraZeneca’s agreement with the Inclusive Vaccines Alliance, announced Saturday, is the latest in a string of deals for access to its COVID-19 vaccine. The U.K. pharma has now committed to provide several global organizations and countries with a total 2.1 billion doses of AZD1222, which it licensed from the University of Oxford.

AstraZeneca plc (LSE:AZN; NYSE:AZN) will supply IVA with up to 400 million doses of the vaccine, formerly ChAdOx1 nCoV-19, at no profit. Deliveries are expected to begin by year-end.

IVA’s members include France, Germany, Italy and the Netherlands, though the organization said it aims to make the vaccine available to other European countries that wish to join the initiative.

Since May, AZ has closed at least four other access agreements.

AZ partnered with the Serum Institute of India Pvt. Ltd. to supply 1 billion vaccine doses for low and middle-income countries under a deal with the international Access to COVID-19 Tools (ACT) Accelerator (see “Three CEPI-funded Vaccines Secure Additional Manufacturing Resources”).

The pharma has also committed to provide 700 million doses through agreements with the U.K., the U.S., the Coalition for Epidemic Preparedness Innovations (CEPI) and Gavi, the Vaccine Alliance. AZ did not respond to an inquiry regarding how many doses each partner will receive.

In May, U.K. Business Secretary Alok Sharma said the government has provided €131 million ($163.9 million) collectively to the vaccine programs from Oxford and Imperial College London; and the Trump administration’s Operation Warp Speed pledged up to $1.2 billion to support clinical development and manufacturing of AZD1222.

This month, CEPI and Gavi said they would provide AZ with $750 million to support the manufacturing and distribution of 300 million doses of AZD1222.

AZ said it has a total manufacturing capacity of two billion doses. The pharma, which expects its European supply chain to begin production soon, said it is also open to additional collaborations to ensure it meets its commitment to support access to the COVID-19 vaccine during the pandemic.

Oxford is enrolling about 10,000 adult volunteers to receive AZD1222 in a Phase II/III trial. The recombinant adenovirus vaccine encodes the SARS-CoV-2 spike protein.

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers